- Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc (NYSE:MRK).
- The platform, also utilized in the vaccine candidate’s Phase 2b study, will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
- In January, Personalis approved a reduction in its workforce by up to approximately 30% to reduce operating costs and improve operating efficiency.
- The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023.
- Price Action: PSNL shares are up 26.80% at $3.86 on the last check Friday.
Warehouse Manager Retires After $8K Shiba Inu Bet Reaps Him $500K — What If He Had Held On To SHIB?
A 35-year-old former supermarket warehouse manager, Rob, achieved early retirement thanks to a remarkable turn of events involving his $8,000 investment in the meme cryptocurrency Dogecoin (CRYPTO: DOGE) killer Shiba Inu (CRYPTO:
